MARC SCHEGERIN - 14 Jan 2022 Form 4 Insider Report for Morphic Holding, Inc.

Role
CFO and COO
Signature
/s/ Robert Farrell as attorney-in-fact for Marc Schegerin, M.D.
Issuer symbol
N/A
Transactions as of
14 Jan 2022
Net transactions value
$0
Form type
4
Filing time
19 Jan 2022, 18:11:28 UTC
Previous filing
03 Nov 2021
Next filing
16 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MORF Stock Option (right to buy Common Stock) Award $0 +85,632 $0.000000 85,632 14 Jan 2022 Common Stock 85,632 $44.75 Direct F1
transaction MORF Restricted Stock Units (RSU) Award $0 +18,760 $0.000000 18,760 14 Jan 2022 Common Stock 18,760 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 2.0833% of the total shares monthly, beginning February 14, 2022, with 100% of the total shares vested and exercisable on January 14, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F3 The RSUs vest as to 25% of the total shares on each of January 14, 2023, January 14, 2024, January 14, 2025, and January 14, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.